feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Brain Scans Show Weight Drug Quiets Food Cravings

Brain Scans Show Weight Drug Quiets Food Cravings

18 Nov, 2025

•

Summary

  • A GLP-1 weight-loss drug temporarily suppressed food cravings in brain scans.
  • Direct brain activity measurements show drug's impact on 'food noise'.
  • Findings suggest potential for eating disorder treatments with future drug versions.
Brain Scans Show Weight Drug Quiets Food Cravings

Researchers monitoring brain activity in a patient with a severe binge-eating disorder observed that Eli Lilly's GLP-1 weight-loss drug, tirzepatide, temporarily silenced food-craving signals in the brain's reward center. This marks the first direct measurement of brain activity in a person receiving tirzepatide, offering insights into its effect on 'food noise.'

The study, published in Nature Medicine, involved monitoring a patient undergoing deep-brain stimulation for loss-of-control eating disorders. One participant, who was prescribed tirzepatide for diabetes and obesity, showed a remarkable lack of food preoccupation and silent nucleus accumbens food-craving signals during initial monitoring.

While the drug's impact on binge-eating was temporary, suggesting it was optimized for diabetes and weight loss rather than eating disorders, the findings are promising. Researchers believe future GLP-1 drugs could be redesigned to target the brain's reward mechanisms for more lasting effects on severe food preoccupation.

trending

Nipah virus in West Bengal

trending

Vivo X200T India launch soon

trending

Smriti Mandhana leads RCB team

trending

Tata Punch facelift features revealed

trending

JKBOSE 12th Exam Schedule

trending

MI Cape Town wins toss

trending

Delhi temperature drops amid cold

trending

Paris FC knocks out PSG

trending

Juventus beats Cremonese 5-0

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Tirzepatide appeared to temporarily suppress food-craving signals in the nucleus accumbens, the brain's reward center, in one observed patient.
While current findings are preliminary, they suggest future versions of GLP-1 drugs like tirzepatide might be adapted for treating certain eating disorders.
'Food noise' refers to food preoccupation. Tirzepatide temporarily silenced these signals and reduced food preoccupation in one study participant.

Read more news on

Healthside-arrow

You may also like

Abivax Soars on Eli Lilly Acquisition Rumors

13 hours ago • 16 reads

article image

Lilly Pill: Weight Loss Convenience Ahead

7 hours ago • 4 reads

article image

Teva Loses Bid to Delay Paragard Lawsuit

1 hour ago

article image

New Triple-Action Drug Promises Major Weight Loss

13 hours ago • 4 reads

article image

Weight Loss Jabs: Gain Back Pounds Faster Than You Lose Them

8 Jan • 28 reads

article image